knowledge -WSS

knowledge

author：explore 2025-10-01 00:52:38 - browse：647

Illustration fo a pink arrow pointing downward. -- biotech coverage from STAT — Adobe

SAN DIEGO — Ventyx Biosciences reported on Monday that it was ending development of an experimental drug for treating plaque psoriasis though it proved safe and moderately effective in a mid-stage trial. Within hours, the company’s stock tanked by more than 80%.

That’s because the company announced that the small molecule, VTX958, had not met the biotech’s internal goals to advance to the next phase of clinical development. Ventyx said it would end work on the drug, which targets the signaling molecule TYK2, as a treatment for psoriasis and psoriatic arthritis.

Shares in Ventyx plummeted from $14.09 at market close to as little as $2.72 during after-hours trading. In the process, the company’s market value dropped from $830 million to around $160 million. Ventyx is now trading below its cash balance, which was $300 million as of the end of September.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： How Vertex's cystic fibrosis drug is changing patients' lives

WSS

CommonSpirit Health keeps growing, even as it loses money

Changes to biosimilar regulatory framework must prioritize patients

As AI in medicine takes off, can 'human in the loop' prevent harm?

Medicare coverage of Wegovy, once blocked, now looks possible

Intarcia’s device

Biotech lab space demand falls sharply

explore

knowledge

knowledge

The high cost of giving birth even with insurance

UCLA team creates talking throat patch for voice disorders

After affirmative action ruling, medical educators look to 'holistic review'

Biotech lab space demand falls sharply

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Senate HELP committee spars over health care workforce policies

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Senate HELP committee spars over health care workforce policies

Anesthesiologist group: stop taking Ozempic before surgery

AstraZeneca, Daiichi breast cancer treatment succeeds in trial

knowledge

Pushing for an NIH office for post

Readout Newsletter: CAR

Amylyx ALS drug fails trial: Relyvrio patients react with fear, worry

How Vertex's cystic fibrosis drug is changing patients' lives

FDA panel to weigh approval of NurOwn, controversial ALS drug

Why scientists need input from humanists on sensitive research

explore

focus

Wikipedia

hotspot